Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133829 | 0.90 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CDMAPT | |
| SCHEMBL4138240 | 0.90 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CDHTT | |
| SCHEMBL4128479 | 0.89 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGPIK3CDHTT | |
| SCHEMBL4143852 | 0.89 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGPIK3CDMAPT | |
| SCHEMBL4147474 | 0.89 | ABCG2 (0.60) | PIK3CAPIK3CBPIK3CGPIK3CDABCG2 | |
| SCHEMBL4140294 | 0.88 | PIK3CA (0.70) | PIK3CAPIK3CBPIK3CGPIK3CDMAPT | |
| SCHEMBL4140239 | 0.88 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CGPIK3CDABCG2 | |
| SCHEMBL4138231 | 0.87 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CDMAPT | |
| SCHEMBL4145858 | 0.86 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CGPIK3CDHTT | |
| SCHEMBL4134975 | 0.85 | PIK3CA (0.53) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | claimed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1945627-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | PIK3CA 137/4885PIK3CB 377/4885PIK3CG 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.